Abstract
To the Editor: Alopecia areata (AA) is an autoimmune disorder that causes hair loss and has an unpredictable course.1 The identification of Janus kinase inhibitors for use in patients with AA has led to multiple studies evaluating novel therapeutics.2 Although placebo-controlled trials remain the gold standard, recruiting and maintaining patients to receive placebo treatment can be challenging because patients may be subjected to months of therapy, with no potential benefit. Herein, we assessed placebo group regrowth rates (PGRRs) across AA clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
